Impact of the coronavirus disease 2019 (COVID-19) pandemic on invasive pneumococcal disease and risk of pneumococcal coinfection with severe acute respiratory …

Z Amin-Chowdhury, F Aiano, A Mensah… - Clinical infectious …, 2021 - academic.oup.com
Background Streptococcus pneumoniae coinfection with influenza results in synergistic
lethality, but there are limited data on pneumococcal coinfection with severe acute …

Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era

S de Miguel, M Domenech… - Clinical Infectious …, 2021 - academic.oup.com
Background Introduction of pneumococcal conjugate vaccines (PCVs) has reduced the
disease caused by vaccine serotypes in children, providing herd protection to adults …

Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges

EK Horn, MD Wasserman, C Hall-Murray… - Expert Review of …, 2021 - Taylor & Francis
Introduction Modeling analyses have attempted to quantify the global impact of
pneumococcal conjugate vaccines (PCVs) on pneumococcal disease (PD), however these …

Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children

N Lecrenier, A Marijam, J Olbrecht… - Expert review of …, 2020 - Taylor & Francis
Introduction: Pneumococcal diseases (including pneumonia, meningitis and sepsis) are
among the leading vaccine-preventable causes of death in under-5-year-olds. Pneumococci …

Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage of Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a randomised controlled …

D Dula, B Morton, T Chikaonda, AE Chirwa… - The Lancet …, 2023 - thelancet.com
Background The effect of childhood pneumococcal conjugate vaccine implementation in
Malawi is threatened by absence of herd effect. There is persistent vaccine-type …

The Impact of the COVID-19 Pandemic on Invasive Pneumococcal Disease and the Risk of Pneumococcal Coinfection with SARS-CoV-2: Prospective National Cohort …

Z Amin-Chowdhury, F Aiano, A Mensah, C Sheppard… - 2020 - papers.ssrn.com
Background: Streptococcus pneumoniae coinfection with seasonal and pandemic influenza
results in synergistic lethality, but there are limited data on pneumococcal coinfection with …

Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom

M Wilson, A Lucas, D Mendes, A Vyse, B Mikudina… - Vaccines, 2023 - mdpi.com
Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a
1+ 1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs …

[HTML][HTML] Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis

R Chapman, K Sutton, D Dillon-Murphy, S Patel… - Vaccine, 2020 - Elsevier
Pneumococcal disease is a substantial contributor to illness and death in young children
globally. The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 had …

Prevalence and serotype distribution of nasopharyngeal carriage of Streptococcus pneumoniae among healthy children under 5 years of age in Hainan Province …

J Wang, L Qiu, S Bai, W Zhao, A Zhang, J Li… - Infectious Diseases of …, 2024 - mednexus.org
Background The thirteen-valent pneumococcal conjugate vaccine (PCV13) is not included
in the national immunization program and is administered voluntarily with informed consent …

Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1+ 1 infant schedule …

YH Choi, M Bertran, DJ Litt, SN Ladhani… - The Lancet Public …, 2024 - thelancet.com
Background Paediatric pneumococcal conjugate vaccine (PCV) programmes in England
using seven-valent PCV (PCV7) in 2006 and 13-valent PCV (PCV13) in 2010 have reduced …